Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01838564 · ClinicalTrials.gov registry record · NA

The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology

A NA study of Quality of Life and Palliative Care, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
104
Enrollment target
4
Study locations

NCT01838564 is a NA study of Quality of Life and Palliative Care that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 104 participants, below the 452-participant average among 107 other Quality of Life trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01838564, a NA study of Quality of Life and Palliative Care, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target
4
Study locations

Study Summary

Over 50% of children dying from cancer still suffer from symptoms that could be effectively alleviated. The purpose of the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study was to evaluate whether providing feedback to families and providers about how the child is feeling improved child distress and quality of life (QoL) in children with advanced cancer. PediQUEST is a computerized survey that asks the child and/or parents how the child has been feeling, i.e. whether the child had any physical or emotional symptoms, as well as how other aspects of life, such as school and friends, are going. After the survey is complete a report that summarizes patient/parent answers is printed. When a child reports moderate to high distress from any symptom an email is automatically sent to the primary providers (oncologist, nurse, and psycho-social clinician as well as the pain and palliative care services) alerting them about the child's distress. In this study we evaluated whether using PediQUEST and providing printed reports to parents and providers reduced distress and improved quality of life in children with advanced cancer. In addition, we wanted to understand whether it was feasible to carry out a randomized controlled trial in children with advanced cancer. Finally, the data collected, will be used to describe the natural history of symptoms and quality of life as reported by the children. Children enrolled in the study (or their parents) were asked to complete a PediQUEST survey at most once a week. A random half of the children received the feedback intervention, i.e. patients, parents, and providers received printed reports (and emails if the child was in distress). The other half only completed the PediQUEST surveys and did not receive reports. We analyzed data collected over 20 weeks of follow-up to see whether receiving PediQUEST reports had any effect on child distress and quality of life.

Interventions

  • OTHER Routine Data collection
  • OTHER Feedback of patient-reported outcomes

Study Locations (4)

Massachusetts

  • Boston Children's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Pennsylvania

  • Children's Hospital of Philapdelphia - Philadelphia

Washington

  • Seattle Children's Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2004-11
Est. Completion 2010-06
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT01838564

The ClinicalTrials.gov registry entry for NCT01838564 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 452-participant average among 107 other Quality of Life trials with a reported enrollment target (77% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Quality of Life appearing as the primary indexed condition, and to 2 interventions - of which Routine Data collection is the first listed.

NCT01838564 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Washington.

Frequently Asked Questions

What is clinical trial NCT01838564 about?

NCT01838564 is a clinical study titled "The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology". Over 50% of children dying from cancer still suffer from symptoms that could be effectively alleviated. The purpose of the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study was to evaluate whether providing feedback to families and providers about how the child is fee...

What is the current status of trial NCT01838564?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2004-11. Estimated completion is 2010-06.

What conditions does trial NCT01838564 study?

This clinical trial studies the following conditions: Quality of Life, Palliative Care, Pediatric Neoplasm, Outcome Assessment.

What interventions are being tested in trial NCT01838564?

The interventions under investigation include: Routine Data collection (OTHER), Feedback of patient-reported outcomes (OTHER).

Who is sponsoring clinical trial NCT01838564?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01838564 being conducted?

This trial has 4 study locations across Massachusetts, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Quality of Life

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.